Open Access. Powered by Scholars. Published by Universities.®
Pharmacoeconomics and Pharmaceutical Economics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Biotechnology (2)
- Drug development (2)
- Absurdity (1)
- Acquisitions (1)
- Antidepressants (1)
-
- Assortment graduation (1)
- Biomimicry (1)
- Biotechnology company (1)
- Clinical trials (1)
- Entropy (1)
- Expert evaluation (1)
- FDA (1)
- Fellowships (1)
- Field marketing research (1)
- Fulfilment (1)
- Industry (1)
- Initial public offering (1)
- Mergers (1)
- Oppression (1)
- Patents (1)
- Pharmaceutical firms (1)
- Pharmaceuticals (1)
- Publication
- Publication Type
Articles 1 - 5 of 5
Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics
Graduation Of Antidepressant Assortment By The Method Of Expert Evaluations On The Pharmaceutical Market Of The Republic Of Uzbekistan, Abror Rahimov
Graduation Of Antidepressant Assortment By The Method Of Expert Evaluations On The Pharmaceutical Market Of The Republic Of Uzbekistan, Abror Rahimov
Problems and Perspectives in Pharmaceutics and Drug Discovery
In the condition of the pharmaceutical market of Uzbekistan, for the first time, we carried an expert evaluation of the nomenclature of antidepressant drugs, considering the competence of experts and the representativeness of respondents of the studied group of drugs. Marketing research was carried out to study the opinions of psychiatrists from Tashkent city for two months: September – October 2020. As a tool for measuring the opinions of experts, an expert survey questionnaire was developed in advance with specified criteria. The study of antidepressants used in domestic conditions was carried out under the international non-proprietary name (INN). Also, based …
Late-Stage Product Development And Approvals By Biotechnology Companies After Initial Public Offering, 1997-2016, Laura M. M. Mcnamee, Ekaterina Galkina Cleary, Sunyi Zhang, Usama Salim, Fred D. Ledley
Late-Stage Product Development And Approvals By Biotechnology Companies After Initial Public Offering, 1997-2016, Laura M. M. Mcnamee, Ekaterina Galkina Cleary, Sunyi Zhang, Usama Salim, Fred D. Ledley
Natural & Applied Sciences Faculty Publications
Purpose: This work describes the late-stage product portfolios of the biotechnology companies that completed initial public offerings (IPOs) from 1997 to 2016. We asked whether these emerging companies continue to develop innovative, biologic products and produce the innovation promised by the early biotechnology industry.
Methods: We identified therapeutic products that reached Phase III development from 1997 to 2016, the characteristics of the products, the dates of the initiation of Phase III and product approval, proxy indicators of the innovativeness of each product, and the contribution of each biotechnology company. Companies were characterized by IPO window and clinical status of the …
The Pharmaceutical Industry: A Pharmacy Student's Guide, Christian Egly, Yaman Kaakeh
The Pharmaceutical Industry: A Pharmacy Student's Guide, Christian Egly, Yaman Kaakeh
Purdue Journal of Service-Learning and International Engagement
Christian Egly is a fourth-year (P4) pharmacy student in the Purdue University College of Pharmacy. During his years at Purdue, he worked in labs performing bench research in clinical pharmacology and biochemistry. He plans to work in the pharmaceutical industry after graduation. During his fourth year, he completed rotations in business development at Kashiv Pharma, LLC, and was hired there for an internship in 2017. In the article, Christian describes his personal experiences at Kashiv Pharma, LLC, and how industry can positively affect patient communities.
Radical Social Ecology As Deep Pragmatism: A Call To The Abolition Of Systemic Dissonance And The Minimization Of Entropic Chaos, Arielle Brender
Radical Social Ecology As Deep Pragmatism: A Call To The Abolition Of Systemic Dissonance And The Minimization Of Entropic Chaos, Arielle Brender
Student Theses 2015-Present
This paper aims to shed light on the dissonance caused by the superimposition of Dominant Human Systems on Natural Systems. I highlight the synthetic nature of Dominant Human Systems as egoic and linguistic phenomenon manufactured by a mere portion of the human population, which renders them inherently oppressive unto peoples and landscapes whose wisdom were barred from the design process. In pursuing a radical pragmatic approach to mending the simultaneous oppression and destruction of the human being and the earth, I highlight the necessity of minimizing entropic chaos caused by excess energy expenditure, an essential feature of systems that aim …
Evaluating The Target Pipeline In A Pharmaceutical Acquisition, Daniel Vass
Evaluating The Target Pipeline In A Pharmaceutical Acquisition, Daniel Vass
Business and Economics Honors Papers
Many firms in the pharmaceutical industry turn to acquisitions when faced with gaps in their drug development pipelines and patent expirations as an alternative to making long-term investments in internal research and development. Investors are generally negative on this strategy, and upon the announcement of a pharmaceutical acquisition the stock of the acquiring firm often drops. This decline in share price creates an opportunity for the investor who can identify the characteristics of a target firm that increase the probability that the transaction will ultimately be a success, as measured by the subsequent appreciation in the acquirer's stock. It is …